4.6 Review

The long and sinuous road to phage-based therapy of Clostridioides difficile infections

Journal

FRONTIERS IN MEDICINE
Volume 10, Issue -, Pages -

Publisher

FRONTIERS MEDIA SA
DOI: 10.3389/fmed.2023.1259427

Keywords

Clostridioides (Clostridium) difficile infection; bacteriophage (phage); phage therapy; endolysin; diffocin; avidocin; phage engineering

Ask authors/readers for more resources

With the antibiotic crisis and the rise in antimicrobial resistance, new therapeutic alternatives are urgently needed. Phage therapy shows promise as an alternative, but there are challenges in treating pathogens like Clostridioides difficile. No strictly lytic phages have been identified for C. difficile, and its antiphage mechanisms and spore resistance complicate therapeutic interventions. However, recent advances in phage engineering and host recognition offer potential solutions for phage therapy in C. difficile.
With the antibiotic crisis and the rise in antimicrobial resistance worldwide, new therapeutic alternatives are urgently needed. Phage therapy represents one of the most promising alternatives but for some pathogens, such as Clostridioides difficile, important challenges are being faced. The perspective of phage therapy to treat C. difficile infections is complicated by the fact that no strictly lytic phages have been identified so far, and current temperate phages generally have a narrow host range. C. difficile also harbors multiple antiphage mechanisms, and the bacterial genome is often a host of one or multiple prophages that can interfere with lytic phage infection. Nevertheless, due to recent advances in phage host receptor recognition and improvements in genetic tools to manipulate phage genomes, it is now conceivable to genetically engineer C. difficile phages to make them suitable for phage therapy. Other phage-based alternatives such as phage endolysins and phage tail-like bacteriocins (avidocins) are also being investigated but these approaches also have their own limitations and challenges. Last but not least, C. difficile produces spores that are resistant to phage attacks and all current antibiotics, and this complicates therapeutic interventions. This mini-review gives a brief historical overview of phage work that has been carried out in C. difficile, presents recent advances in the field, and addresses the most important challenges that are being faced, with potential solutions.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available